New Neupogen Formula More Temperature Stable

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 5
Volume 6
Issue 5

THOUSAND OAKS, Calif--A new formulation of Neupogen (filgrastim or G-CSF) that contains sorbitol instead of mannitol is now available from Amgen.

THOUSAND OAKS, Calif--A new formulation of Neupogen (filgrastim or G-CSF)that contains sorbitol instead of mannitol is now available from Amgen.

The new formulation has the same clinical safety and efficacy profileas the mannitol-containing version, but offers additional flexibility withrespect to storage parameters.

Sorbitol-containing Neupogen will remain stable even if exposed to freezingtemperatures, as might occur in transit. The recommended storage temperaturewill continue to be 2° to 8° C. However, the gel tray insulationand freeze watch indicators required with mannitol-containing Neupogenwill be eliminated, allowing for smaller packaging and reduced need forrefrigerator inventory space.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content